295 related articles for article (PubMed ID: 30115703)
1. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
2. Untangling the Role of Polycomb Complexes in Chemotherapy Resistance.
Duy C; Melnick A
Cancer Discov; 2018 Nov; 8(11):1348-1351. PubMed ID: 30385522
[No Abstract] [Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
5. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Long J; Parkin B; Ouillette P; Bixby D; Shedden K; Erba H; Wang S; Malek SN
Blood; 2010 Jul; 116(1):71-80. PubMed ID: 20404136
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
7. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
9. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
[TBL] [Abstract][Full Text] [Related]
10. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
11. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.
Wurz RP; Cee VJ
J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
13. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
[TBL] [Abstract][Full Text] [Related]
14. ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53.
Li L; Feng Y; Hu S; Du Y; Xu X; Zhang M; Peng X; Chen F
J Cell Mol Med; 2021 Jun; 25(11):5295-5304. PubMed ID: 33960640
[TBL] [Abstract][Full Text] [Related]
15. The effect of cantharidins on leukemic stem cells.
Dorn DC; Kou CA; Png KJ; Moore MA
Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
[TBL] [Abstract][Full Text] [Related]
16. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
[TBL] [Abstract][Full Text] [Related]
17. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
18. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
19. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
20. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin.
Bollaert E; Claus M; Vandewalle V; Lenglez S; Essaghir A; Demoulin JB; Havelange V
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]